Compare Davita Inc (DVA) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Invesco NASDAQ 100 ETF — how do they compare? Davita Inc trades at $179.49 (market cap $11.38B), while Invesco NASDAQ 100 ETF trades at $298.57. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | QQQM | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $307.23 |
52-Week Low | $103.87 | $229.87 |
Enterprise Value | $24.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
QQQM trades at $298.50, up 0.58% with a bullish technical outlook supported by moving averages. The ETF tracks the Nasdaq-100 index with exposure to large-cap tech stocks. Recent news highlights QQQM's lower expense ratio advantage over QQQ at $15 annually versus $18, making it an attractive cost-efficient option for Nasdaq-100 exposure. The fund has demonstrated strong historical performance with approximately 14% average annual returns since inception.
The outlook remains positive given Nasdaq's tech-led rally potential in H2 2026, though investors face concentration risk in mega-cap tech holdings. Key risks include market volatility and potential regulatory scrutiny of large tech companies. QQQM offers efficient Nasdaq-100 exposure with competitive fees for long-term growth investors seeking tech sector leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
